Anti Inflammatory News and Research

RSS

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

25 Nov 2015

Brain imaging reveals distinctive aspects of high-inflammation depression

About one third of people with depression have high levels of inflammation markers in their blood. New research indicates that persistent inflammation affects the brain in ways that are connected with stubborn symptoms of depression, such as anhedonia, the inability to experience pleasure.

21 Nov 2015

BUSM researchers identify new fingerprint of inflammation in obesity-associated type 2 diabetes

There is strong evidence that inflammation promotes obesity-associated type 2 diabetes and diabetes complications. However, clinical trials with anti-inflammatory drugs have only been modestly effective for treating Type 2 diabetes. A new fingerprint of inflammation that may be able to predict which patients with obesity may also develop type 2 diabetes has been identified by Boston University School of Medicine researchers.

19 Nov 2015

Use of aconitine may lead to severe poisoning, warns Chinese physicians report

Chinese physicians report on the case of a woman who presented with aconitine-induced cardiovascular symptoms. Their report, published in the Canadian Journal of Cardiology, warns that the use of this natural ingredient may lead to severe poisoning.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

ProMetic Life Sciences Inc. announced today that it has entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived Inter-alpha Inhibitor Proteins.

19 Nov 2015

Identifying new mechanism for aspirin in cancer prevention

Aspirin has been shown to decrease the risk of colorectal cancer and possibly other cancers. However, the risk of side effects, including in some cases severe gastrointestinal bleeding, makes it necessary to better understand the mechanisms by which aspirin acts at low doses before recommending it more generally as a preventative, says Cornelia Ulrich, PhD, Senior Director of Population Sciences at Huntsman Cancer Institute in Salt Lake City.

19 Nov 2015

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Respiratory infections are common in preschoolers, but while most children recover fairly easily from the typical coughs and congestion, a significant number develop illnesses severe enough to interfere with breathing and warrant trips to urgent care clinics or emergency rooms.

18 Nov 2015

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

Mucus plays important role in defending invaders

By licking a wound it heals faster - this is not simply popular belief, but scientifically proven. Our saliva consists of water and mucus, among other things, and the mucus plays an important role. It stimulates white blood cells to build a good defence against invaders, according to a group of researchers at Lund University in Sweden together with colleagues from Copenhagen and Odense in Denmark.

6 Nov 2015

University of Leicester awarded BBSRC grant to explore three key areas that impact human health

The University of Leicester has been awarded over £1.5 million in order to advance knowledge and understanding in three key areas that impact on health.

5 Nov 2015

Harnessing the brain's immune system to combat Alzheimer's disease

A new study appearing in the Journal of Neuroinflammation suggests that the brain's immune system could potentially be harnessed to help clear the amyloid plaques that are a hallmark of Alzheimer's disease.

5 Nov 2015

Study highlights importance of sex-specific differences in complex biological processes

New research published in the Journal of Leukocyte Biology shows that male and female mice respond differently to inflammation at the cellular level. Specifically, in male mice the spleen acts as a source of white blood cells, while in females this is not the case. This discovery suggests that human studies are necessary to determine if current medical practices, which treat men and women generally the same, should be altered to reflect sex-specific differences.

3 Nov 2015

Diet missing soluble fiber promotes inflammation in the intestines, leading to weight gain

Eating too much high-fat, high-calorie food is considered the primary cause of obesity and obesity-related disease, including diabetes. While the excess calories consumed are a direct cause of the fat accumulation, scientists suspect that low-grade inflammation due to an altered gut microbiome may also be involved.

30 Oct 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

New generation of incretin-based medicines allows coordinated action against diabesity

The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases.

28 Oct 2015

WSU collaborates with Botanisol to study and develop new anti-inflammatory drug

Work on a new anti-inflammatory drug developed from the medicinal/spice plant turmeric recently received funding from a $225,000 grant from the National Institutes of Health National Center for Complementary and Integrative Health.

28 Oct 2015

Anti Inflammatory News and Research

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Brain imaging reveals distinctive aspects of high-inflammation depression

BUSM researchers identify new fingerprint of inflammation in obesity-associated type 2 diabetes

Use of aconitine may lead to severe poisoning, warns Chinese physicians report

Lilly, Merck expand oncology clinical trial collaboration

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

Identifying new mechanism for aspirin in cancer prevention

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Mucus plays important role in defending invaders

University of Leicester awarded BBSRC grant to explore three key areas that impact human health

Harnessing the brain's immune system to combat Alzheimer's disease

Study highlights importance of sex-specific differences in complex biological processes

Diet missing soluble fiber promotes inflammation in the intestines, leading to weight gain

Scientists one step closer to developing new treatment for inflammatory bowel disease

New generation of incretin-based medicines allows coordinated action against diabesity

WSU collaborates with Botanisol to study and develop new anti-inflammatory drug

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News